Le Lézard
Classified in: Health
Subjects: TRI, FDA, FVT

Nashville surgeon to be the first in Tennessee to surgically implant the first and only trifocal lens in the U.S.

NASHVILLE, Tenn., Aug. 30, 2019 /PRNewswire/ -- Jeffrey D. Horn, MD, owner of Vision For Life in Nashville, is set to be the first to surgically implant the new FDA approved PanOptix Trifocal Intraocular Lens on Wednesday, Sept. 4, and you are invited to the procedure and interview the surgeon and the patient pre- and post-operatively.

A limited number of media will also be granted access to video the procedure.

The first surgery since gaining FDA approval is slated to begin at 11 a.m. at The Eye Surgery Center of Middle Tennessee. Below is the address and the tentative interview schedule. Times may vary as it's a busy surgery day.

210 25th Ave. N., Suite 920., Nashville, TN 37203

8 a.m. ? 8:15 a.m. ? Dr. Horn pre-op interview

8:45 a.m. ? 9:10 a.m. ? Patient pre-op interview

10:40 a.m. ? 10:55 a.m. ? Dr. Horn pre-op interview

11 a.m. ? 11:30 a.m. ? Surgery (cameras will be allowed in O.R. on a limited basis)

11:30 a.m. ? 11:45 a.m. ? Dr. Horn post-op interview

11:45 a.m. ? 12 p.m. ? Patient post-op interview

"This is an extremely exciting advancement in the treatment of cataract surgery," Horn said. "The trifocal lens corrects vision at all distances and is quite simply the best lens I have ever implanted."

The FDA approval of PanOptix was based on a pivotal study at 12 investigational sites in the U.S., including Vision For Life here in Nashville, being led by Dr. Horn.

With this single trifocal lens design, PanOptix patients demonstrated exceptional, uninterrupted vision. The results also showed high patient satisfaction with more than ninety-nine percent of PanOptix patients saying they would choose the same lens again.

According to Alcon, the manufacturer of the PanOptix lens, more than 4 million cataract surgeries are performed each year in the U.S., which is projected to increase by more than 16 percent by the end of 2024.

Cataracts are the most common age-related eye condition and the leading cause of preventable blindness. Twenty million people in the U.S. age 40 and older have cataracts, but they can be reversed with surgery. Cataracts are treated by removing the eye's cloudy natural lens and surgically replacing it with an intraocular lens or IOL. More than 98 percent of cataract surgeries are considered successful, and patients typically can return to their normal routines within 24 hours.

"It is, quite simply, the best lens I've ever implanted." Horn said. "The results of the trial are incredible."


Matt Hudson/Brass Advertising   

SOURCE Jeffrey D. Horn, MD Vision For Life

These press releases may also interest you

at 16:05
Rocket Pharmaceuticals, Inc. ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the closing of its previously announced underwritten public...

at 16:05
Horizon Therapeutics plc today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.S. Food and Drug Administration (FDA) voted unanimously that the potential benefits of teprotumumab, a fully human monoclonal...

at 16:02
Michael D. Most, MD, FACS, is being recognized by Continental Who's Who as a Pinnacle Lifetime Achiever in the field of Medicine in recognition of his role as a Surgeon. Backed by twelve years of experience, Dr. Most is one of the top head and neck...

at 16:01
K-Bro Linen Inc. (the "Corporation") announced today a dividend of 10.00 cents CDN per common share of the Corporation for the period from December 1 to 31, 2019, to be paid on January 15, 2020 to holders of record of common shares on December 31,...

at 16:00
Attainia today announced that Michael Burns has been named VP, Sales. With more than 1,000 member hospital locations, Attainia is the world's most widely used equipment planning, budgeting, and tracking system software for healthcare equipment. "I am...

at 16:00
The Muscular Dystrophy Association (MDA) today celebrated the decision by the US Food and Drug Administration (FDA) to grant accelerated marketing approval to golodirsen (Vyondys 53) for the treatment of Duchenne muscular dystrophy (DMD) in patients...

News published on 30 august 2019 at 12:48 and distributed by: